Overview

A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

Status:
Completed
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Guard Therapeutics AB
Treatments:
Pharmaceutical Solutions